Alnylam to present new analyses at Heart Failure 2026 underscoring consistent clinical profile of Vutrisiran in ATTR-CM
Alnylam Pharmaceuticals, Inc announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026,… read more.
